The purpose of this study is to evaluate the safety and efficacy of LY4515100 and see how a single oral dose compares with placebo in acute postsurgical pain after removing impacted third molars. For each participant, the study may last approximately 6 weeks and will include a stay in a Clinical Research Unit (CRU) after third molar removal.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
212
JBR Clinical Research
Salt Lake City, Utah, United States
Change from Baseline in Self-Reported Pain Intensity
Time frame: Baseline, Up to Day 1
Time to Reduction in Pain Intensity as Measured by an 11-Item Numerical Scale
Time frame: Baseline, Up to Day 1
Change in Self-Reported Pain Relief as Measured by 5-Item Categorical Scale
Time frame: Baseline, Up to Day 1
Time to Rescue Medications
Time frame: Baseline, Up to Day 1
Participants Overall Impression of Pain Relief on a Five-Point Scale
Time frame: Baseline, Up to Day 1
Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY4515100
Time frame: Baseline, Up to Day 1
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
CONTACT
Physicians interested in becoming principal investigators please contact
CONTACT
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.